Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF – Get Rating) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 1,900 shares, a growth of 18.8% from the November 30th total of 1,600 shares. Based on an average trading volume of 3,700 shares, the short-interest ratio is currently 0.5 days.
Algernon Pharmaceuticals Trading Down 3.2 %
Shares of AGNPF stock opened at $1.63 on Friday. The business's 50 day simple moving average is $1.98 and its 200 day simple moving average is $2.77. Algernon Pharmaceuticals has a one year low of $1.52 and a one year high of $9.28.
Get
Algernon Pharmaceuticals alerts:
About Algernon Pharmaceuticals
(Get Rating)
Algernon Pharmaceuticals Inc operates as a clinical stage pharmaceutical development company. It focuses on the areas of non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia.
Read More
- Get a free copy of the StockNews.com research report on Algernon Pharmaceuticals (AGNPF)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
Receive News & Ratings for Algernon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Algernon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
阿爾傑農製藥公司(場外交易市場代碼:AGNPF-GET Rating)是空頭股數12月份實現顯著增長的目標。截至12月15日,空頭股數共有1,900股,較11月30日的1,600股增長18.8%。以平均成交量3,700股計算,目前短息比率為0.5天。
Algernon製藥公司股價下跌3.2%
AGNPF股票上週五開盤報1.63美元。該業務的50日簡單移動均線切入位為1.98美元,200日簡單移動均線切入位為2.77美元。Algernon PharmPharmticals的一年低點為1.52美元,一年高位為9.28美元。
到達
阿爾傑農製藥公司警報:
關於Algernon製藥公司
(獲取評級)
Algernon製藥公司是一家臨床階段藥物開發公司。它集中在加拿大和澳大利亞與新冠肺炎相關的非酒精性脂肪性肝炎、慢性腎臟疾病、炎症性腸道疾病、特發性肺纖維化、慢性咳嗽和急性肺損傷等領域。
閱讀更多內容
- 免費獲取StockNews.com關於Algernon製藥的研究報告(AGNPF)
- MarketBeat:回顧一週12/26-12/30
- 科技狗:是時候咬一口這些股票了
- 這筆收購會讓微軟成為熊市買入者嗎?
- 你應該暖身到Generac股票過冬嗎?
- 金塔拉治療公司是一顆隱藏的寶石嗎?
獲得Algernon PharmPharmticals Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Algernon製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。